

ASX Announcement

Hong Kong Patent Granted for RECCE® Anti-Infectives

Sydney Australia, 27 November 2025: Recce Pharmaceuticals Limited (**ASX:RCE, FSE:R9Q**), (**Recce or the Company**) a leading developer of a New Class of Synthetic Anti-Infectives, is pleased to announce the Hong Kong Special Administrative Region has formally granted Patent Family 4 for Recce's Anti-Infectives, expiry 2041.

The Hong Kong Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), most notably:

- **Process for preparation of RECCE® anti-infectives**
- **Use of R327/R529 for the treatment of disease, particularly in treatment of bacterial infections, viral infections and more**
- Specifically, further validating RECCE® anti-infectives from studies in **Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Diabetic Foot Infections (DFI), Burn Wounds, Lung Infections (including Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia), Urinary Tract Infections, Gonorrhoea, Influenza, SARS-CoV2**
- **Administration by oral, inhalation, transdermal delivery or by injection (into the bloodstream, intramuscular and/or intravenous)**
- **Administration may also be supplied as an aerosol, gel, topical foam or ointment (or impregnated into a dressing for application to skin or mucous membranes for transdermal or transmucosal delivery)**

This is the Company's sixth Family 4 patent, alongside Australia, Canada, Israel, Japan and China, with further Patent Cooperation Treaty (PCT) submissions in respective stages of review/allowed. The Hong Kong pharmaceutical market is valued at around US\$2.5 billion and projected to grow at a 6.5% CAGR from 2025 to 2030¹.

¹ <https://healthcareasiamagazine.com/healthcare/news/hong-kong-pharmaceutical-market-be-valued-3b-2028>



Recce continues to progress its Phase 3 clinical trial in Indonesia, as it seeks further approval pathways across ASEAN markets. The strengthening of its intellectual property portfolio in nations such as Hong Kong, further supports this regional strategy, enabling market entry opportunities in territories where demand for next-generation anti-infectives continues to grow.

Recce Pharmaceuticals' Chief Executive Officer, James Graham said: "Securing the Family 4 patent in Hong Kong marks an important expansion of our intellectual property footprint across Asia. This protection strengthens our ability to advance a New Class of Anti-Infectives in a region with substantial medical and commercial significance."

This announcement has been approved for release by Recce Pharmaceuticals Board.

Media and Investor Relations

Chief Executive Officer
James Graham
Recce Pharmaceuticals Ltd
james.graham@recce.com.au

Australia
Andrew Geddes
Seed Media
andrew@seedmedia.com.au

USA & Europe
Guillaume van Renterghem
LifeSci Advisors
gvanrenterghem@lifesciadvisors.com

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.

Media and Investor Relations

Chief Executive Officer
James Graham
Recce Pharmaceuticals Ltd
james.graham@recce.com.au

Australia
Andrew Geddes
Seed Media
andrew@seedmedia.com.au

USA & Europe
Guillaume van Renterghem
LifeSci Advisors
gvanrenterghem@lifesciadvisors.com